<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546945</url>
  </required_header>
  <id_info>
    <org_study_id>Asmaa Hassan</org_study_id>
    <nct_id>NCT04546945</nct_id>
  </id_info>
  <brief_title>Aberrant Expression of CD56 in Patients With Hematologic Malignancies.</brief_title>
  <official_title>Resident Doctor at Clinical Pathology Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asmaa Hassan mohamed Abdel Mawjoud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma&#xD;
      . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in&#xD;
      AML. To the best of our knowledge, no available data the expression pattern of CD56 in other&#xD;
      Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in&#xD;
      hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD56 is the archetypal phenotypic marker of natural killer cells but can actually be&#xD;
      expressed by many more immune cells, including alpha, beta T cells, gamma, delta T cells,&#xD;
      dendritic cells, and monocytes. Common to all these CD56 expressing cell types have strong&#xD;
      immunostimulatory effector functions, including T helper 1 cytokine production and an&#xD;
      efficient cytotoxic capacity. Interestingly, both numerical , functional deficiencies and&#xD;
      phenotypic alterations of the CD56 immune cell fraction have been reported in patients with&#xD;
      various infectious, autoimmune, or malignant diseases.CD56 is also known as neural cell&#xD;
      adhesion molecule (NCAM).&#xD;
&#xD;
      Hematologic malignancies are a heterogeneous group of diseases of diverse incidence,&#xD;
      prognosis and etiology that arise from malignant transformation of cells from the bone marrow&#xD;
      or the lymphatic system.There are two major groups of Hematologic malignancies according to&#xD;
      their cell lineage: Myeloid and lymphoid. Lymphoid neoplasms are a varied group that includes&#xD;
      non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia and multiple myeloma (MM).myeloid&#xD;
      neoplasms and acute leukaemia include: Myeloproliferative neoplasms (MPN),&#xD;
      Myelodysplastic/myeloproliferative neoplasms (MDS/MPN), Myelodysplastic syndromes (MDS),&#xD;
      Acute myeloid leukaemia (AML), Acute leukemias of ambiguous lineage, B-lymphoblastic&#xD;
      leukaemia/lymphoma, T-lymphoblastic leukaemia/lymphoma.The exact causes of Hematologic&#xD;
      malignancies are still unknown although multiple epidemiological studies have reported an&#xD;
      association between the development of Hematologic malignancies and several risk factors.&#xD;
      Some factors are well documented to increase the risk of some types of leukaemia such as&#xD;
      benzene exposure and ionizing radiation.However, many other factors were observed to have an&#xD;
      association with Hematologic malignancies such as age, gender, tobacco smoking , obesity ,&#xD;
      hepatitis C virus (HCV) infection , family history , and environmental exposure to pesticides&#xD;
      but with no clear evidence.&#xD;
&#xD;
      CD56 was found to be ectopically expressed in multiple myeloma. A met analysis indicated that&#xD;
      CD56 over expression may be an adverse prognostic factor in AML. To the best of our&#xD;
      knowledge, no available data the expression pattern of CD56 in other Hematologic&#xD;
      malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic&#xD;
      malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>To identify the Pattern of expression of CD56 in hematologic malignancies.</measure>
    <time_frame>1 years</time_frame>
    <description>Expression of aberrant CD56 in hematologic malignancies by flowcytometry. To explore incidence of Expression of aberrant CD56 in hematologic malignancies .&#xD;
Correlation between this expression and outcome of the patient.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>control cases</arm_group_label>
    <description>normal healthy person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with hematologic malignancies. Newly diagnosed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CD56</intervention_name>
    <description>detection of CD56 by flow cytometry</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>control cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hematologic malignancies Newly diagnosed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies.&#xD;
&#xD;
          -  Newly diagnosed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic disorders other than hematologic malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged S Mahmoud, prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.google.com/search?q=Kelly-Rogers+J%2C+Madrigal-Estebas+L%2C+O%E2%80%99Connor+T%2C+Doherty+DG.+Activation-induced+expression+of+CD56+by+T+cells+is+associated+with+a+reprogramming+of+cytolytic+activity+and+cytokine+secretion+profile+in+vitro.+Hum+Immunol+(2006)&amp;oq=Kelly-Rogers+J%2C+Madrigal-Estebas+L%2C+O%E2%80%99Connor+T%2C+Doherty+DG.+Activation-induced+expression+of+CD56+by+T+cells+is+associated+with+a+reprogramming+of+cytolytic+activity+and+cytokine+secretion+profile+in+vitro.+Hum+Immunol+(2006)+&amp;aqs=chrome..69i57.1761j0j15&amp;sourceid=chrome&amp;ie=UTF-8</url>
    <description>(1) Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol (2006)</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601173/</url>
    <description>Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013)</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27686372/</url>
    <description>(3) Van Acker HH, Anguille S, Willemen Y, Van den Bergh JM, Berneman ZN, Lion E, et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol (2016)</description>
  </link>
  <link>
    <url>https://www.frontiersin.org/articles/10.3389/fimmu.2017.00892/full</url>
    <description>Heleen H. Van Acker,* Anna Capsomidis, Evelien L. Smits, and Viggo F. Van Tendeloo ( CD56 in the Immune System: More Than a Marker for Cytotoxicity?) Published 2017 frontiers in immunology.</description>
  </link>
  <link>
    <url>https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)30280-0/abstract</url>
    <description>(5) Flowers CR, Glover R, Lonial S and Brawley OW: Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/20664057/</url>
    <description>(6) Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM, et al: Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood.</description>
  </link>
  <link>
    <url>https://ashpublications.org/blood/article/117/19/5019/20991/The-2008-WHO-classification-of-lymphoid-neoplasms</url>
    <description>(7) Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H and Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/19357394/</url>
    <description>(8)Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008 revision of the World Health Organization (WHO)</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/26980727/</url>
    <description>(9) Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27069254/</url>
    <description>(10) A. Arber, Attilio Orazi,Hasserjian, J ¨urgen Thiele,J. Borowitz,Le Beau, D. Bloomfield, Cazzola, and W. Vardiman : The 2016 revision to the World Health Organization classification of myeloid neo</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/17311819/</url>
    <description>(11) Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/8218879/</url>
    <description>(12) Floderus B, Persson T, Stenlund C, Wennberg A, Ost A, Knave B. Occupational exposure to electromagnetic fields in relation to leukemia and brain tumors: a case-control study in Sweden. Cancer Causes Control 1993</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635414/</url>
    <description>(13) Kedia S, Bhatt VR, Rajan SK, Tandra PK, El Behery RA, Akhtari M. Benign and malignant hematological manifestations of chronic hepatitis C virus infection. Int J Prev Med 2014.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/26597998/</url>
    <description>(14) Pan Y, Wang H, Tao Q, Zhang C, Yang D, Qin H, et al. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Res (2016)</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/25924702/</url>
    <description>(15) Xu S, Li X, Zhang J, Chen J. Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis. J Cancer Res Clin Oncol (2015)</description>
  </link>
  <link>
    <url>http://jtd.amegroups.com/article/view/16406/html</url>
    <description>(16) Hazra A. Using the confidence interval confidently. J Thorac Dis 2017.</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Asmaa Hassan mohamed Abdel Mawjoud</investigator_full_name>
    <investigator_title>resident doctor clinical pathology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

